No score here is dominant — that is the point. A small real lift on attention and memory, a modest preserved-memory signal in older adults whose cognition is starting to slip, and a ~14% peak-force bump for alpha-GPC on max-effort lifts. Cheap enough to try, controversial enough that the Korean stroke signal makes any cardiovascular history a real reason to default to citicoline. The catch most marketing pages skip: the two biggest trials, in acute stroke and severe head injury, were both clean nulls.
Both compounds work as choline delivery vehicles that actually get to the brain — the thing the cheaper choline supplements (lecithin, choline bitartrate) mostly fail to do. Once inside neurons, citicoline gets re-assembled into the building block that maintains neuronal membranes; alpha-GPC gets stripped to free choline, the precursor to a chemical messenger called acetylcholine — what your memory and attention systems run on. That's the same system prescription Alzheimer's drugs like donepezil target by a different route; raising the supply is mechanistically sound.
The honest open question is whether your brain's choline supply is actually the bottleneck in normal day-to-day life, well-fed and not yet aging. Most adults don't hit the daily choline target from food alone IOM 1998, and a long-running Framingham cohort linked higher dietary choline to better verbal memory and fewer of the small white-matter lesions that creep in with age Poly 2011. That argument leans on eggs and liver first; the supplement is a backup when the diet won't carry the weight.
What the trials actually show
Picture the version of you who has been taking 500 mg of citicoline every morning for two months. Sit-down focus on a hard task gets a little easier; the second hour, when your attention used to drift, holds a little better. Not a stimulant lift, not a click. A small, steady change that shows up on a stopwatch attention task more reliably than in your felt experience. That's roughly what the cleanest healthy-adult trial produced — and roughly what the literature consistently produces in healthy people: real but small.
The signal gets bigger when the starting point is lower. In older adults whose memory has started to slip — early vascular cognitive impairment, mild Alzheimer's — these compounds preserved memory scores for months in trials where the untreated arms declined. The Cochrane review of citicoline in cognitive disorders of the elderly pooled ten trials and landed on modest, real benefit on memory and behaviour, with the usual caveats about size and sponsorship Fioravanti 2005.
What didn't work: the big swings. The two largest, best-funded trials in this whole literature gave a much higher dose for acute brain injury — 2 grams a day after stroke, 2 grams a day after severe head injury — and got nothing. Functional recovery, cognitive recovery, mortality: indistinguishable from placebo. Citicoline is not a stroke drug; the marketing residue that says otherwise is from older, smaller trials the big ones failed to replicate.
For alpha-GPC, there is a separate, narrower claim worth taking seriously: peak force on max-effort lifts. Two small trials in trained lifters found about a 14% bump in peak bench-press force taken about an hour before the heaviest set. Useful for a meet day; not a substitute for caffeine, and it does not feel like one.
How to take it
Doses are not adventurous. The cognitive trials that produced the cleanest signals used the lower end of the range, and going higher mostly does not buy more effect. Take with food in the morning — both can produce mild evening alertness if dosed late.
Trials in older adults have run citicoline at 1 g/day for nine months without trouble; the higher dose buys a little more in cognitively-declining populations and nothing extra in healthy ones. The acute-injury trials that tested 2 g/day got no benefit at any endpoint — that dose has no remaining use case outside research.
When to skip — and when to switch to citicoline
The day-to-day safety profile is benign: rare stomach upset, occasional headache, mild insomnia if dosed too late. The two large stroke and head-injury trials, running thousands of patients at the high 2 g/day dose, found no serious-event signal versus placebo Dávalos 2012 Zafonte 2012. Two specific cardiovascular cautions are worth knowing about anyway.
The second concern is more general and sits underneath both compounds. Dietary choline gets converted by gut bacteria into a compound called TMAO, and independent cardiology cohorts have linked higher TMAO levels to heart attacks and strokes Wang 2011 Tang 2013. Whether daily choline supplementation pushes TMAO into the range that matters, on top of what eggs and meat already deliver, has not been properly measured — but the mechanism is established and the cardiology community takes it seriously. A reasonable hedge: don't stack supplemental choline on top of an already egg-heavy, red-meat-heavy diet without a reason.
Pregnancy and breastfeeding have no specific safety data either direction; the precautionary call is to skip. Citicoline has mild blood-thinning activity in animal data; if you are on therapeutic anticoagulation, run it past the prescribing clinician before adding either.
Three things the marketing copy gets wrong
"Any choline supplement does the same job." Lecithin and choline bitartrate are cheaper and they do raise blood choline, but they cross into the brain poorly. Citicoline and alpha-GPC are the two oral forms with documented brain-choline elevation at sensible doses Conant 2004. If the bottle is generic and the label cost less than $5, the contents are doing less than the label implies.
"Citicoline speeds stroke recovery." The two largest trials say no Dávalos 2012 Zafonte 2012. The earlier, smaller, mostly-positive citicoline trials are why this claim still circulates; the big ones failed to replicate them. Take it for the cognitive support it actually delivers, not for the neuroprotection it doesn't.
"Alpha-GPC works like a pre-workout stimulant." It produces a small bump in peak force on max-effort sets and almost no subjective stimulation. People expecting a caffeine-like click conclude it's doing nothing — it is, quietly, on a narrow slice of physical performance. If you want stimulation, use caffeine; if you want a marginal lift on the heaviest single, alpha-GPC is doing something small and real.
Cheaper, often better, almost always first
Before reaching for either capsule, the cheaper move is dietary. Three eggs a day meets the male adult choline target without any supplement; a single 100 g serving of beef liver covers most of a week's intake. The Framingham data linking higher dietary choline to better memory was built on what people ate, not what they capsulised Poly 2011.
For sharper acute attention in healthy adults, caffeine has a far bigger evidence base at a fraction of the cost. For age-related cognitive decline that's gone past mild, prescription cholinesterase inhibitors (donepezil, rivastigmine, galantamine) are what the neurology guidelines actually recommend; citicoline and alpha-GPC sit as adjuncts at best, not substitutes. For pre-workout power, caffeine, creatine, and beta-alanine all have larger trial bases — alpha-GPC competes only on the narrow peak-force endpoint on maximal-effort sets, which is exactly when caffeine is already there.
Why people try this and conclude it does nothing
The most common failure mode is expecting it to feel like something. It mostly doesn't. Cognitive effects show up on stopwatch tasks over weeks; day one is usually "I don't think anything happened." That isn't the supplement failing — it's the supplement working at the size the studies say it works at. Most people who notice nothing on week one notice nothing on week eight either, because there isn't much to notice in a healthy young adult; the populations where you'd actually expect to feel a difference are older people whose memory is starting to slip.
The corollary failure mode is escalating the dose to chase a felt click that isn't there. 2 grams a day is what the negative stroke trials used; it doesn't help healthy people more than 500 mg, and it raises the chance of mild headache, queasiness, or evening insomnia. Stay at the lower end. If nothing is happening at week eight, the answer is probably to stop, not to go higher.
What it costs, what to buy
Both are sold as over-the-counter supplements in the US, EU, UK, and most of Asia. In Korea, alpha-GPC is prescription-only and its indications were narrowed after the 2021 cohort signal Lee 2021. Expect to spend $15–30 a month on either at standard doses — roughly $150–350 a year for one of them.
Two label-reading points. Cognizin is the trademarked citicoline that almost every published cognitive trial used; generic citicoline (anhydrous CDP-choline) is chemically identical and considerably cheaper, and the trial literature reads onto it. Alpha-GPC quality varies more — a powder labelled "alpha-GPC 50%" is often 50% by weight active and 50% by weight silica carrier. The number that matters is milligrams of alpha-GPC per serving, not milligrams of powder.
Adjacent worth a look: dietary choline sources (eggs, liver, soy) — the cheaper first move; creatine for cognition, the other gym-store supplement with credible trial evidence; caffeine, the cheapest cognitive intervention with the largest evidence base; and the prescription cholinesterase inhibitors a neurologist would actually reach for in age-related cognitive decline. The wider TMAO question — whether dietary choline, red meat, and gut-bacteria composition translate to real cardiovascular events — runs into territory this entry does not try to settle.
Substance and claimed effects
Citicoline (cytidine-5'-diphosphocholine, CDP-choline) and alpha-GPC (L-alpha-glycerylphosphorylcholine) are two of the more bioavailable choline-donor compounds marketed as daily nootropics. Both cross the blood-brain barrier and feed the brain's pool of free choline, which is the rate-limiting precursor for acetylcholine synthesis and a substrate for phosphatidylcholine in neuronal membranes Grieb 2014 Secades 2016. Marketed claims cluster in four buckets: (1) memory and attention in healthy adults, (2) cognitive function in age-related decline and mild vascular cognitive impairment, (3) neuroprotection / brain aging via membrane phospholipid turnover, and (4) acute power output in trained lifters (alpha-GPC). This entry covers all four, plus the cardiovascular / stroke controversy that the choline-donor literature has accumulated over the last decade (gut-microbial conversion to TMAO, plus a Korean cohort signal specific to alpha-GPC).
Evidence by addressing question
Mechanism
The pathway is the Kennedy cycle — the biosynthetic route that builds phosphatidylcholine, the dominant phospholipid in neuronal membranes. Citicoline is the proximal intermediate of this cycle: dietary citicoline hydrolyses to cytidine and choline in the gut, both cross the BBB, and reform CDP-choline inside the cell, where it donates its choline-phosphate head group to diacylglycerol to make phosphatidylcholine Grieb 2014. Alpha-GPC sits one step further upstream: it is a phosphatidylcholine breakdown product (~40% choline by weight) that the brain uses primarily as a free-choline source for acetylcholine synthesis and for re-synthesising membrane phospholipids Parnetti 2007.
Two downstream effects matter clinically. First, raising free choline raises acetylcholine output from cholinergic neurons — the same neurotransmitter system that cholinesterase inhibitors (donepezil, rivastigmine) target in Alzheimer's. Second, supporting phosphatidylcholine resynthesis is hypothesised to slow age-related membrane attrition and the ischaemic membrane-lipid breakdown that follows stroke — the original rationale for citicoline's stroke trials Conant 2004. The cytidine moiety of citicoline (converted to uridine in humans) additionally enters the pyrimidine salvage pathway, providing substrate for membrane phospholipid synthesis beyond the choline arm. Mechanism is real; the open question is whether the brain's choline pool is actually limiting under normal conditions in a healthy, well-fed adult.
Evidence
Evidence is uneven across the four claim buckets.
Cognition in healthy adults. Small. A 28-day RCT in 60 healthy adult women (250 mg vs 500 mg vs placebo) found dose-dependent improvement on a sustained-attention task (Ruff 2 & 7), with the 250 mg arm showing the cleanest signal — but the trial was small (n=60), sponsored, and used a single attentional task McGlade 2012. There is no large, well-powered RCT showing meaningful cognitive enhancement in young, neurologically healthy adults at the doses sold over the counter.
Cognition in older adults and mild cognitive impairment. Modestly positive. A 12-week RCT in healthy older adults (mean age 70) found citicoline 1 g/day improved verbal memory in the subgroup with poorer baseline memory Spiers 1996. The IDEALE study — 9-month open-label, n=265, mild vascular cognitive impairment — found citicoline 1 g/day preserved MMSE versus a declining control arm Cotroneo 2013. The Cochrane review of CDP-choline for cognitive disorders in the elderly (10 trials, n≈1300) concluded modest short- and medium-term benefit on memory and behaviour, but flagged heterogeneity and small trial sizes Fioravanti 2005. For alpha-GPC, the De Jesus Moreno trial — 261 mild-to-moderate Alzheimer's patients, alpha-GPC 1.2 g/day for 180 days — found improvement on ADAS-Cog and Clinical Global Impression versus placebo De Jesus Moreno 2003. The combined picture: a small, real effect in cognitively declining populations; less convincing in healthy controls.
Acute stroke and TBI. Negative at the trial scale most weight is given to. The ICTUS trial (n=2298, citicoline 2 g/day vs placebo, 90-day functional recovery) was unambiguously null Dávalos 2012. The COBRIT trial (n=1213, citicoline for complicated mild, moderate, or severe traumatic brain injury, 90-day functional and cognitive endpoints) was likewise null Zafonte 2012. These two large, high-quality RCTs effectively closed the door on citicoline as an acute neuroprotectant for stroke and TBI, despite earlier positive smaller trials and a plausible mechanism. Chronic post-stroke recovery is a slightly different question with weaker evidence, but the acute trials are the load-bearing negatives.
Power output (alpha-GPC). Small positive signal in trained lifters. A crossover trial in resistance-trained men (n=13, alpha-GPC 600 mg vs placebo 45 min pre-lift) found increased peak bench-press force (~14%) but no significant change in mean force or rate of force development Bellar 2015. A separate RCT (n=48, alpha-GPC 250 mg or 500 mg vs placebo) found a small increase in vertical-jump peak force versus caffeine controls Marcus 2017. Effect sizes are small, samples are small, and the underlying mechanism (transient acetylcholine availability at the neuromuscular junction, possibly via a growth-hormone spike Ceda 1992) is plausible but not nailed down. This is "useful for a peak-set on a competition day," not "transforms training."
Dietary background. Most adults don't hit the choline Adequate Intake (425 mg/day for women, 550 mg/day for men) from food alone IOM 1998. The Framingham Offspring cohort found higher dietary choline associated with better verbal memory and fewer white-matter hyperintensities Poly 2011. This is the strongest argument for daily choline support in midlife — but it argues for diet (eggs, liver, soy) first, with supplemental donors as backup.
Protocol
Standard daily doses, derived from the trial literature: citicoline 250–500 mg once daily (the McGlade attention signal sat at 250 mg; the older-adult cognitive trials use 500–1000 mg); alpha-GPC 300–600 mg once daily for chronic use, or 600 mg taken 30–60 minutes pre-lift for the acute-power use case. Both are typically taken with food, in the morning, because of mild alerting effects. There is no taper requirement. Trials have run 4–24 weeks without dose adjustment; longer-term safety data exist out to ~12 months in older adult cohorts Cotroneo 2013 De Jesus Moreno 2003. Higher doses (citicoline 2 g/day, the ICTUS/COBRIT dose) show no additional cognitive benefit and bring no obvious safety signal but no upside either.
Contraindications
The published safety profile of both compounds is benign in short-to-medium-term trials: rare GI upset, mild headache, transient insomnia if dosed late. ICTUS and COBRIT (citicoline 2 g/day, thousands of patients) found no serious adverse-event signal versus placebo Dávalos 2012 Zafonte 2012.
Two cardiovascular flags are worth taking seriously. Alpha-GPC and stroke risk: a Korean nationwide cohort (n≈12,000 alpha-GPC users matched to n≈12,000 non-users, 10-year follow-up) found alpha-GPC use associated with a 43% higher all-cause stroke incidence and an 86% higher haemorrhagic-stroke incidence Lee 2021. The study is observational and confounding-by-indication is a real concern (alpha-GPC is prescribed in Korea for early cognitive decline, a population with elevated baseline cerebrovascular risk), but the magnitude is large enough that the Korean Ministry of Food and Drug Safety narrowed indications in response. TMAO and atherosclerosis: dietary choline (and lecithin) is metabolised by gut bacteria to trimethylamine, then by hepatic FMO3 to trimethylamine-N-oxide (TMAO); higher TMAO is associated with major adverse cardiovascular events in independent cohorts Wang 2011 Tang 2013. Whether supplemental choline donors raise TMAO enough to matter clinically, on top of dietary choline, has not been adequately quantified — but the mechanism is well-characterised and the eggs-and-meat-cohort literature is suggestive.
Practical implications: prior stroke or established cardiovascular disease is a reason to default to citicoline over alpha-GPC and to keep doses at the lower end. Pregnancy and breastfeeding have no specific safety data either way; precautionary avoidance is the standard call. Citicoline has weak antiplatelet activity in some animal data; combination with therapeutic anticoagulation is a "ask the prescriber" call.
Misconceptions
Three common ones. "Choline donors are interchangeable with dietary choline." Phosphatidylcholine (lecithin) and choline bitartrate raise plasma choline but cross the BBB poorly; citicoline and alpha-GPC are the two oral forms with documented brain-choline elevation Conant 2004. The other forms are cheaper but mechanistically weaker. "Citicoline works for stroke recovery." The acute trials are clean negatives Dávalos 2012 Zafonte 2012. The "citicoline for post-stroke recovery" framing in supplement marketing is residue from the earlier, smaller, mostly-positive trials that the large RCTs failed to replicate. "Alpha-GPC is a workout pre-load that works like a stimulant." The power-output effect is small (~10–15% peak force in tiny trials), specific to maximal-effort lifts, and probably mediated by acute acetylcholine availability rather than CNS arousal. It is not a substitute for caffeine and does not produce subjective stimulation at standard doses.
Alternatives
For the dietary-choline backstop use case: eggs (~150 mg per yolk), beef liver (~350 mg per 100 g), soybeans, cruciferous vegetables. Three eggs a day meets the male AI without supplementation. For cognitive support in healthy adults: caffeine has a far larger evidence base and effect size for acute attention; creatine 5 g/day has emerging cognitive evidence (separate entry) at a similar cost. For age-related cognitive decline: prescription cholinesterase inhibitors (donepezil) are the evidence-supported pharmacologic answer if cognition is impaired enough to warrant treatment; citicoline / alpha-GPC are adjuncts, not substitutes. For pre-workout power: caffeine (200–400 mg), creatine, beta-alanine all have larger trial bases.
Failure modes
Most common failure mode: expecting a felt, stimulant-like effect and concluding the supplement is doing nothing. Choline-donor effects on attention and memory are modest and accrete over weeks, not minutes; the McGlade and Spiers signals were on validated tests, not self-report. A second failure mode: taking too high a dose (chasing a felt effect that isn't there) and running into mild headache or GI symptoms. A third: stacking with cholinesterase inhibitors without flagging it to the prescribing clinician.
Practicalities
Both are sold as supplements in the US, EU (with some country variation), UK, and most of Asia outside Korea. In Korea, alpha-GPC is prescription-only and indications have been narrowed since the 2021 cohort signal. Cost: citicoline ~$15–25/month at 500 mg/day; alpha-GPC ~$15–30/month at 600 mg/day. Cognizin is the trademarked citicoline formulation that most of the human trials used; generic citicoline is chemically identical and substantially cheaper. Alpha-GPC quality varies more — some "alpha-GPC 50%" powders are 50% alpha-GPC, 50% silica carrier; the label needs reading.
Stakes and payoff
Stakes are mild. Choline donors are not a load-bearing intervention for any major disease endpoint in a healthy adult; deferring or skipping does not, on the available evidence, cost meaningful life-years or function. The Framingham observational signal on dietary choline is the strongest "stakes" argument, but it points at the diet, not the supplement Poly 2011. Payoff in healthy adults is correspondingly small: at best, a modest sustained-attention lift over weeks and a slightly cleaner pre-set on max-effort lift days. In older adults with mild cognitive complaints, payoff is larger but still modest — preserved MMSE in vascular cognitive impairment, marginally better ADAS-Cog in early AD — and is sensibly framed as adjunctive to whatever the neurologist is doing, not a replacement for it.
The credibility range
Optimist case
The mechanism is real and well-characterised. Most adults don't hit the choline AI from diet. The brain-aging literature consistently links cholinergic decline to memory loss, and the only FDA-approved AD drugs target the same system. Multiple modest-positive trials across decades — McGlade in healthy women, Spiers in older adults, Fioravanti's Cochrane review, IDEALE in vascular cognitive impairment, De Jesus Moreno in mild AD — converge on "modest cognitive benefit, decent tolerability." The negative acute-stroke and TBI trials test a different hypothesis (acute neuroprotection at 2 g/day in catastrophic injury) and don't speak to chronic preventive use. Alpha-GPC's power-output signal, while small, is mechanistically coherent and survives across two independent labs. The cost is trivial and the safety record is clean. For a 55-year-old with a thin choline diet who notices their memory isn't what it was, daily citicoline 500 mg is one of the cheaper rational hedges available.
Skeptic case
The two largest, best-funded, best-powered trials (ICTUS, COBRIT) were unambiguously null, and the rest of the literature is small, often sponsored, often run by groups with commercial ties (notably Italian research groups with alpha-GPC manufacturer relationships). The Cochrane review's "modest benefit" reads as faint-praise; the trials it pooled are heterogeneous and underpowered. Healthy young adults have no compelling evidence base. The Korean cohort signal on alpha-GPC stroke risk — even granting confounding-by-indication — is a 40–86% hazard elevation that would be career-defining for any approved drug. TMAO is a real downstream concern that the supplement literature has not engaged with seriously. The "modern diets are choline-deficient" argument leads to eggs, not capsules. For most readers, this is a low-evidence purchase that pays a small attention dividend that caffeine would deliver more cheaply.
Author's call
Real but small effect on attention and memory; meaningfully larger in cognitively declining older adults than in healthy young ones; legitimate small acute power effect for alpha-GPC at the gym. The acute-stroke and TBI failures are decisive against the neuroprotection hype but don't refute the modest cognitive-support claim, which sits on different (smaller) trials. The alpha-GPC stroke signal is the most important caveat — observational, confounded, but not dismissible — and it pushes the default toward citicoline for anyone with cardiovascular history. Net rating: a low-mid evidence intervention with a modest, real-but-not-transformative payoff, best framed as an honest dietary-choline backstop and adjunct for cognitive decline rather than a nootropic miracle. The supplement industry massively oversells it; the negative-trial readers massively undersell it; the truth is dull and useful.
Stakeholder and incentive map
Commercial: Cognizin (Kyowa Hakko) is the dominant trademarked citicoline; most positive citicoline trials in healthy adults used this material. Italfarmaco and other European manufacturers commercialise alpha-GPC under prescription branding in some markets. Most independent power-output studies on alpha-GPC have either industry funding or material donation; this is the default in sports-nutrition research and is disclosed but worth noting. Clinical: neurology guidelines (AAN, EAN) do not endorse choline donors for AD or stroke; the IDEALE-style vascular-cognitive-impairment use is a European clinician practice more than a guideline. Community: the nootropics subculture (Reddit r/Nootropics, Examine.com forums, biohacker podcasts) has elevated both compounds well past their evidence base, often pairing them with racetams in regimens that the literature does not support. Counter-incentive: the cardiology and microbiome communities have surfaced the TMAO concern and the Korean stroke signal; their voice is roughly absent from supplement marketing.
Population variability
Three sub-populations matter. Older adults with mild cognitive decline or vascular cognitive impairment are the group with the largest positive trial signal and the clearest dose-response — this is who the European trials enrolled Cotroneo 2013 De Jesus Moreno 2003. Adults on low-choline diets (low egg, low meat, low liver intake; many plant-forward eaters and dieters) have the most plausible deficiency to correct, per the Framingham associations Poly 2011. Trained lifters interested in peak-set performance are the acute-power use case for alpha-GPC. Outside these groups — healthy 25-year-olds on a normal Western diet — the evidence base is essentially silent and the marketing claim base is loudest. There is no strong gender modifier in the trials (McGlade was women-only by design, not by finding). Genetic variation in choline metabolism (PEMT, BHMT, MTHFR variants) probably modulates response but has not been mapped in supplementation trials. Race/ethnicity sub-analyses are largely absent.
Knowledge gaps
The big unknowns: (1) does chronic supplementation in healthy midlife adults change long-term cognitive trajectory, or only short-term test performance? — no trial has run long enough to answer; (2) does supplemental choline materially raise TMAO above dietary baseline, and does that translate to measurable cardiovascular events in supplement users? — the linking studies have not been done; (3) is the Korean alpha-GPC stroke signal reproducible in Western cohorts with different prescribing patterns, or is it a confounding artifact of indication? — no independent replication exists; (4) what's the right comparator for healthy-adult cognitive use — placebo (where the signal is faint) or caffeine (where the signal is dwarfed)? — the head-to-heads don't exist; (5) does combination with cholinesterase inhibitors yield additive benefit in early AD? — biologically plausible, not formally tested at scale. Evidence that would shift the author's call: a well-powered TMAO-and-CV-events trial in supplement users (would dial controversy down or kill the entry); a Western replication of the Korean stroke signal (would push alpha-GPC out and citicoline-only in); a long-duration midlife cognition trial (would let the entry make a real preventive claim, or close that door).
Brief vs entry coverage. The brief named memory, focus, brain aging, and physical power output. The article covers focus and memory in healthy adults and in cognitively-declining older adults (evidence section), brain aging via the dietary-choline / Framingham angle (mechanism section), and physical power output for alpha-GPC (evidence section). All four are addressed end-to-end. No narrowing required.
Scope addition the brief did not ask for. The Korean alpha-GPC stroke cohort (Lee 2021) and the TMAO cardiovascular pathway (Wang 2011, Tang 2013) were added to contraindications as load-bearing safety context. Both are the dominant honest reason to default-to-citicoline and to flag cardiac-condition as a contraindication; omitting them would have produced a marketing-shaped entry.
Hard scoring calls.
focus = 2: The Cochrane meta-pooling and IDEALE preserved-MMSE signal could have justified a 3 if the entry were scoped to cognitively-impaired older adults; weighting the modest healthy-adult signal pulled it to 2. The substance produces a meaningful effect in a specific population and a small one in everyone else.energy = 1: The energy dimension's anchor is "daily vitality / less fatigue," which the substance does not deliver. The 1 is paid for entirely by alpha-GPC's peak-force signal on max-effort lifts, which is the closest landing slot in the closed dimension set. A dedicatedphysical_powerdimension would have caught this cleanly; flagged for the rating framework rather than the entry.longevity = 0: Zeroed honestly. There is no positive longevity evidence, and the Lee 2021 cohort plus the TMAO pathway argue the other direction. Not scored negative because the dimension is unsigned.evidence = 2,controversy = 3: The combination reflects honest mid-quality trial evidence plus real, active controversy. ICTUS and COBRIT are decisive against the acute-neuroprotection claim but do not refute the modest cognitive-support claim that the smaller trials support, which is why evidence is not pushed lower.
Dream narrative — relief lever, score below 40. Overall score lands ~14. Dream narrative written with the relief / debunking lever (stop overpaying for the cognitive miracle that isn't) rather than aspiration. The dek and tagline were written straight per §2 rather than from the narrative, but the narrative's relief framing carries through their structure. The §1 marketing-words ban is not lifted on either surface.
Future-link candidates. Creatine (separate entry — has cognitive trial evidence at similar cost); caffeine (the comparator the healthy-adult use case keeps losing to); dietary choline sources / eggs (the first-move alternative); cholinesterase inhibitors (the prescription cognitive treatment for AD); TMAO and cardiovascular risk (the wider cardiometabolic concern). The out-of-scope section signposts all five for the reader.
Separate-entry candidates surfaced. TMAO and gut-bacteria-mediated cardiovascular risk warrants its own entry — it sits behind several supplement and dietary-pattern recommendations. Korean alpha-GPC stroke cohort warrants linking from any future stroke-prevention entry. Cholinesterase inhibitors for early Alzheimer's is its own substantial entry (action: decide, prescription gate).
Contraindication choices. Selected pregnancy, breastfeeding (precautionary — no safety data), cardiac-condition (Lee 2021 + TMAO), blood-thinners (citicoline's weak antiplatelet activity in animal data). Did not flag thyroid-condition, kidney-disease, or others — no signal in the literature.
Citicoline and Alpha-GPC
One capsule with breakfast. Zero behavioural change. Pre-lift timing for alpha-GPC adds a small wrinkle on training days.
Citicoline 500 mg/day runs ~$15–25/month; alpha-GPC 600 mg/day ~$15–30/month. Annual cost lands in the $150–350 range — minor but not trivial for an intervention with modest payoff.
Real but small effect on attention and memory. The Cochrane review (Fioravanti 2005) found modest cognitive benefit in older adults with cognitive disorders; McGlade 2012 showed a sustained-attention lift in healthy women; IDEALE (Cotroneo 2013) preserved MMSE in vascular cognitive impairment. Effect sizes are modest and the healthy-young-adult evidence base is thin.
Mechanism is clean (Kennedy-cycle phosphatidylcholine synthesis, acetylcholine precursor) and the Cochrane review found modest cognitive benefit in cognitively-impaired elderly (Fioravanti 2005). But the two largest, best-powered RCTs — ICTUS in acute stroke and COBRIT in TBI — were unambiguously null (Dávalos 2012, Zafonte 2012). Healthy-adult trials are small, sponsored, and use single-task endpoints.
Modest subjective attentional clarity in some users; the McGlade 2012 RCT in healthy women saw a small sustained-attention lift at 250 mg citicoline. Most healthy adults don't notice anything stimulant-like in the first weeks.
Small acute power-output effect for alpha-GPC in trained lifters — Bellar 2015 found ~14% higher peak bench-press force at 600 mg pre-lift; Marcus 2017 saw a small jump-force lift. Not a daily-vitality compound; the score reflects the narrow gym-day effect.